Sugi Predict

Sugi Predict / Compounds / Adenine

Adenine

Adenine

SCHEMBL3474048

Cc1c[nH]c(=O)[nH]c1=O.Nc1ncnc2[nH]cnc12

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATAD2 Q6PL18 1/20 0.53
▸ PDPK1 O15530 2/20 0.35
▸ PNP P00491 1/20 0.35
▸ ACHE P22303 1/20 0.34
▸ GDA Q9Y2T3 1/20 0.34
▸ PARP1 P09874 4/20 0.34
▸ PI4KA P42356 2/20 0.32
▸ PI4K2B Q8TCG2 2/20 0.32
▸ PI4K2A Q9BTU6 2/20 0.32
▸ PI4KB Q9UBF8 2/20 0.32
▸ LMNA P02545 2/20 0.32
▸ DRD3 P35462 1/20 0.32
▸ XDH P47989 1/20 0.32
▸ LRRK2 Q5S007 1/20 0.32
▸ DPYD Q12882 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ CYP19A1 P11511 1/20 0.31
▸ TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Adenine SCHEMBL4633065 1.00 ATAD2 (0.53) ATAD2PDPK1PNPACHEGDA
Adenine SCHEMBL8472509 1.00 ATAD2 (0.53) ATAD2PDPK1PNPACHEGDA
Guanine SCHEMBL4577873 0.91 ATAD2 (0.43) ATAD2PNPLMNAXDHALDH1A1
Adenine SCHEMBL4579096 0.89 ATAD2 (0.41) ATAD2PNPPARP1
Adenine SCHEMBL6256495 0.87 ATAD2 (0.40) ATAD2
Adenine SCHEMBL6227731 0.84 ATAD2 (0.37) ATAD2
2,6-Diaminopurine SCHEMBL1672826 0.84 ATAD2 (0.50) ATAD2PDPK1PNPACHEGDA
Guanine SCHEMBL17542295 0.83 ATAD2 (0.36) ATAD2PNPLMNAXDHALDH1A1
Guanine SCHEMBL5097008 0.82 ATAD2 (0.36) ATAD2LMNAXDHALDH1A1PMP22
Guanine SCHEMBL9468293 0.82 ATAD2 (0.35) ATAD2LMNAXDHALDH1A1PMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739777-A1 TRANSMISSIBLE ELEMENTS COMPRISING PATHWAY MODIFICATION SYSTEMS AND EXOGENOUS NUCLEIC ACIDS FOR THE PRODUCTION OF MOLECULES OF INTEREST SNIPR Biome ApS (DK) 2026-05-13 — — EP claimed
EP-4574980-A2 A NOVEL TYPE OF CRISPR/CAS SYSTEM SNIPR Biome ApS (DK) 2025-06-25 — — EP claimed
CN-120153077-A Novel CRISPR/Cas system 斯尼普生物群系有限公司 2025-06-13 — — CN claimed
WO-2025008424-A1 TRANSMISSIBLE ELEMENTS COMPRISING PATHWAY MODIFICATION SYSTEMS AND EXOGENOUS NUCLEIC ACIDS FOR THE PRODUCTION OF MOLECULES OF INTEREST SNIPR BIOME APS (DK) 2025-01-09 — — WO claimed
EP-4392563-A1 A NOVEL TYPE OF CRISPR/CAS SYSTEM SNIPR Biome ApS. (DK) 2024-07-03 — — EP claimed
WO-2024047151-A1 A NOVEL TYPE OF CRISPR/CAS SYSTEM SNIPR BIOME APS (DK) 2024-03-07 — — WO claimed
CN-115287272-A Novel dye decoloring method for clone and recombinase of DyP-type peroxidase gene 浙江省农业科学院 2022-11-04 — — CN claimed
WO-2026099341-A1 BIOCONTAINMENT OF UNWANTED ENGINEERED CELLS USING NON-NATURAL AMINO ACIDS SNIPR BIOME APS (DK) 2026-05-15 — — WO disclosed
EP-4739777-A1 TRANSMISSIBLE ELEMENTS COMPRISING PATHWAY MODIFICATION SYSTEMS AND EXOGENOUS NUCLEIC ACIDS FOR THE PRODUCTION OF MOLECULES OF INTEREST SNIPR Biome ApS (DK) 2026-05-13 — — EP disclosed
US-20260109991-A1 PHAGE-DERIVED PARTICLES FOR IN SITU DELIVERY OF DNA PAYLOAD INTO C. ACNES POPULATION ELIGO BIOSCIENCE (FR) 2026-04-23 — — US disclosed
US-20250381212-A1 METHOD FOR TREATING C. ACNES BACTERIA-ASSOCIATED DISEASES ELIGO BIOSCIENCE (FR) 2025-12-18 — — US disclosed
US-12460216-B2 Phage-derived particles for in situ delivery of DNA payload into C. acnes population ELIGO BIOSCIENCE (FR) 2025-11-04 — — US disclosed
US-12454696-B2 Cutibacterium acnes recombinant phages encoding a human protein ELIGO BIOSCIENCE (FR) 2025-10-28 — — US disclosed
WO-1998042722-A1 ANTISENSE INHIBITION OF ANGIOGENIN EXPRESSION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1998-10-01 — — WO disclosed
EP-0820461-A1 CHEMICAL COMPOUNDS MEDICAL RESEARCH COUNCIL (GB) 1998-01-28 — — EP disclosed
EP-0792283-A1 SYNTHESIS OF PEPTIDE NUCLEIC ACIDS (PNAs) AND ANALOGUES VIA SUBMONOMER APPROACH CHIRON CORPORATION (US) 1997-09-03 — — EP disclosed
WO-1996029336-A1 CHEMICAL COMPOUNDS MEDICAL RESEARCH COUNCIL (GB) 1996-09-26 — — WO disclosed
WO-1996015143-A1 SYNTHESIS OF PEPTIDE NUCLEIC ACIDS (PNAs) AND ANALOGUES VIA SUBMONOMER APPROACH CHIRON CORPORATION (US) 1996-05-23 — — WO disclosed
US-4066827-A Process for producing a polyion complex having a nucleic acid base TOYO SODA MANUFACTURING CO., LTD. (JA) 1978-01-03 — — US disclosed
US-4056666-A Process for producing polyion complex having nucleic acid bases TOYO SODA MANUFACTURING CO., LTD. (JA) 1977-11-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109991-A1 PHAGE-DERIVED PARTICLES FOR IN SITU DELIVERY OF DNA PAYLOAD INTO C. ACNES POPULATION CUTA, STAT3, POLL ATAD2 605/4885PDPK1 4744/4885PNP 4380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.